RxDoctor Payments Data

Burhan Mohamedali, MD

Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1831393289

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $98,940 of the $154,228 with a category attached, or 64.2%. 50 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 31.2% of the total.

$154,228in general payments, 2019–2025

Across 1,383 payments — averaging $111.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$48K
  • AstraZeneca$24K
  • Boston Scientific$22K
  • Novartis$16K
  • Abbott$12K
  • Kestra Medical Technology Services, Inc.$8K
  • plus $23K from 44 others
$19,420in research payments, 2019–2025

Across 12 payments — averaging $1618.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Impulse Dynamics (USA) Inc.$19K

What the payments were for

  • Consulting fees$17,21811%
  • Speaking & faculty fees$98,94064%
  • Travel & lodging$2,6762%
  • Food & beverage$34,94323%
  • Education$4510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$154,228 in reported general payments places this provider in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$355,656
Medicare patients
771
Services billed
2,677

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan394$385,742
OpsumitMacitentan24$302,714
FarxigaDapagliflozin Propanediol380$294,199
CamzyosMavacamten31$266,037
EliquisApixaban185$210,407
JardianceEmpagliflozin109$94,163
XareltoRivaroxaban53$62,462
DapagliflozinDapagliflozin Propanediol27$14,921
BrilintaTicagrelor17$8,782
Metoprolol Succinate289$4,490
Ranolazine ErRanolazine32$3,566
Bumetanide80$3,414
Atorvastatin Calcium170$1,623
Amlodipine Besylate208$1,452
Nifedipine ErNifedipine48$1,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$16,028$385,742394 claims
AstraZenecaFarxiga, Brilinta$23,917$302,980397 claims
Actelion Pharmaceuticals US, Inc.Opsumit$48,084$302,71424 claims
E.r. Squibb & Sons, L.L.C.Camzyos$726$266,03731 claims
PfizerEliquis$1,602$210,407185 claims
Boehringer IngelheimJardiance$437$94,163109 claims
Johnson & JohnsonXarelto$1,259$62,46253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →